portal hypertension current status hypertension • defined as an increase in portal vein pressure...
TRANSCRIPT
Portal hypertension
Current Status
Abraham Shaked MD PhD
Portal Hypertension
• Defined as an increase in portal vein pressure
to exceed 6 mmHg
• It is the underlying process responsible for the
most common complications of cirrhosis:
– Ascites
– Variceal bleeding
– Hepatic encephalopathy
Portal circulation
Classification of portal hypertension
(PHTN)
Pre-hepatic
PHTN
Portal v thrombosis
Intrahepatic
PHTN
Presinusoidal
Sarcoidosis
PBC
Schistosomiasis
Sinusoidal
Cirrhosis
Alcoholic Hepatitis
Postsinusoidal
Sinusoid obstruction
syndrome (VOD)
Post-hepatic
PHTN
Budd-Chiari Syndrome
Rt heart failure
Constrictive pericarditis
IVC web
- Fibrosis in the space of Disse
- Compression by regenerative nodules
and fibrous bands
- Swelling of hepatocytes
Histological
Clinical Non-cirrhotic Compensated Compensated Decompensated
Symptoms None None (no varices) None (varices present)Ascites, VH,
encephalopathy
Sub-stage - Stage 1 Stage 2 Stages 3 and 4
Hemodynamic (HVPG,
mmHg)
BiologicalFibrogenesis and
AngiogenesisScar and X-linking
Thick (acellular) scar
and nodulesInsoluble scar
Classification of Chronic Liver Disease
>6 >10 >12
F1-F3 F4 (Cirrhosis)
Garcia Tsao G et al Hepatology 51:145-9;2010
Cumulative Proportion of Patients Transitioning from Compensated to Decompensated Stage Over Time
Pro
po
rtio
n o
f P
atie
nts
1.00
0.75
0.50
0.25
0.00
Pts at risk 806 513 402 302 243 217
months0 24 48 72 96 120
D’Amico G et al. J Hepatol. 2006;44:217-231.
Consequences of PHTN: Ascites
and Hepatorenal SyndromeCirrhosis
Portal HTN
Splanchnic vasodilation
Incr Spl capillary pressure Arterial Underfilling
Na & Water Retention
Impaired free water excretion
Renal vasoconstrictionIncr lymph production
NO
ADH
Angiotensin II
Aldosterone
Norepinephrine
Ascites Hyponatremia Hepatorenal
syndrome
Hypotension
Consequences of PHTN: Varices
and Hepatic Encephalopathy
• Most common sites portosystemic collaterals
- GE junction and proximal stomach:
Gatroesophageal varices
- Umbilical vein: Caput medusae
- Rectum: Rectal varices
• Consequences:
- Increased pressure in collaterals resulting in
rupture: variceal bleeding
- Shunting of gut derived toxins (ammonia)
away from the liver: hepatic encephalopathy
Gastroesophageal varices
Small varices
< 5 mm
Large varices
> 5 mmNo varices
7-8%/year 7-8%/year
Natural history of varices in cirrhosis
Merli et al. J Hepatol 2003;38:266
VARICES INCREASE IN DIAMETER PROGRESSIVELY
• Usually develop as HVPG exceeds 10-12 mmHg
• Tend to grow with time
Cirrhosis35-80 %
Risk of Esophageal Varices
25-40 %
Die
15-20 %80-85 %
Survive
Rebleed
70 %
Bleed
Predictors of variceal bleeding
• Esophageal varices do not usually bleed
until HVPG > 12mmHg
• Bleeding rate: 5-15% / yr
• Risk of bleeding increases:
- Large Varices
- Red marks
- Child B/C
• Mortality of 20 %
• HVPG > 20 mmHg predicts a higher
mortality from variceal bleed (64% at 1 yr)
Baveno IV International Consensus Workshop Staging System for Cirrhosis:
1-Year Outcome Probabilities
NO VARICES
NO ASCITES
VARICES
NO ASCITES
ASCITES
VARICES
BLEEDING
ASCITES
DEATH
Stage 1
Stage 2
Stage 3
Stage 4
Co
mp
en
sa
ted
De
co
mp
en
sate
d
1%
3.4%
20%
57%
4.4%7%
6.6% 4%
7.6%
D’Amico G et al. J Hepatol. 2006;44:217-231.
Non-Selective Beta-Blockers in primary prophylaxis
Bleeding rate Control Beta-blocker Absolute rate(~2 year) difference
All varices 25% 15% -10%
(11 trials) (n=600) (n=590) (-16 to -5)
Large varices 30% 14% -16%(8 trials) (n=411) (n=400) (-24 to -8)
Small varices 7% 2% -5%(3 trials) (n=100) (n=91) (-11 to 2)
D’Amico et al., Sem Liv Dis 1999; 19:475
NON-SELECTIVE BETA-BLOCKERS PREVENT FIRST VARICEAL HEMORRHAGE
• If there are large varices on EGD
- β blockers or EVL
EVL: Q1-2 wks until obliteration, repeat at
1-3 months, then Q 6-12 months
• Once on β blocker for primary prophylaxis,
endoscopy not needed unless there is
need to stop βblocker or GI bleed
Primary prophylaxis for
variceal bleeding
Management of acute
variceal bleeding• Resuscitate:
- IV access, fluids, blood products
- Do not overtransfuse! Target Hb 8 g/dL
• Prophylactic antibiotics x 7 days
• IV Octreotide for 3 - 5 days
Endoscopy / EVL as soon as stabilized
• 10-20% of variceal bleeds are uncontrolled
with the above measures: TIPS
Survival, According to Transfusion Strategy
Villanueva C, et al. N Engl J Med 2013;368:11-21
5
12 11
24
9
22 22
811
0
5
10
15
20
25
Death from anycause within 45
days
Patients withcirrhosis
Bleeding fromesophageal varices
Balloon therapies TIPS
%
Restrictive Strategy
Liberal Strategy
Hemoglobin threshold for transfusion: Randomized trial of restrictive versus liberal transfusion strategies
for acute upper gastrointestinal bleeding Study Outcomes
Villanueva C, et al. N Engl J Med 2013;368:11-21
Restrictive strategy: Transfuse when Hg below 7g/dLLiberal strategy: Transfuse when Hg below 9g/dL
p=0.02p=0.04
p=0.03
p=0.05p=0.02
Blood Transfusion Requirement 15 % Vs.51%
P <0.001
Probability of Remaining Free of Recurrent Variceal Hemorrhage
Hou M-C et al., Hepatology 2004; 39:746
Prophylactic antibiotics (n=59)
%free of
variceal
bleed
1.0
0.6
0.2
0.8
10
No antibiotics (n=61)
02 3 12 30
Follow-up (months)
18 24
0.4
PROPHYLACTIC ANTIBIOTICS PREVENT EARLY VARICEAL REBLEEDING
Gastric Varices
Rx same
as EV
Can be
seen in
Spl. v.
thrombosis
Bleeding gastric fundus
varices
• Tend to be larger, more tortuous, deeper
vessels than EV: present a challenge for
endoscopic therapy
• Can bleed at lower HVPG
• Best endoscopic therapy: cyanoacrylate
injection, but not widely available and
cumbersome
• Low threshold for TIPS in bleeding GV in
the fundus
Transjugular Intrahepatic Portosystemic Shunt
(TIPS)
in the Setting of Intrahepatic and Post-hepatic
Portal Hypertension
PresinusoidalPBC
Sinusoidal
HCV, ETOH
Post-sinusoidal/Post-hepatic
BCS
Outcomes after early TIPS
• dose of propranolol
• use of nitrates
• use of uncovered stents
• exclusion of those with advanced liver disease
García-Pagán JC et al. N Engl J Med 2010;362:2370-2379.
The Blakemore Tube
Portal Vein Thrombosis• Portal vein thrombosis:
• Incidence in compensated disease: 0.6% to 5%
• Incidence in advanced disease: up to 40%
•Risk factors for PVT:• Recurrent liver decompensation
• History of infection, bleeding, endoscopic treatment
• Abdominal surgery (eg. splenectomy)
Ascites
Fatigue
Poor quality of life
Muscle wasting
Umbilical hernia rupture
Hydrothorax
SBP
Hepatorenal Syndrome
Cirrhotic Ascites – Survival
20
40
60
80
100
1 2 3 4 5 6
YearsOnset
Survival
(%)
Management of Ascites
First Line Therapy Second Line Therapy
Tense ascites
Paracentesis
Sodim restriction ( 2 Gm/24 Hrs) and diuretics
Non-tense ascites
• Repeated Large volume
paracentesis (LVP)
•TIPS ? Early
• Liver Transplantation
Refractory Ascites 10 %
•Diuretics: Spironolactone 100 mg/day, furosemide 40 mg/day or
bumetanide 1 mg a day.
•Uptitrate stepwise to spironolactone 400 mg/day, furosemide 160
mg/day or bumetanide 4 mg/day as long as it is tolerated
•Post paracentesis albumin infusion
may not be necessary for < 5 liters removed
• Albumin infusion of 6-8 gm/liter of fluid
removed is a consideration for repeated LVP
20
40
60
80
100
1 2 3 4 5 6
YearsOnset
Survival
(%)
Ascites Survival: Only improved by liver transplant
After Liver Transplant
Surgical Resection of HCC in Cirrhosis
(not to be done by the general surgeon)
0
1020
30
4050
60
70
8090
100
0 20 40 60 80
Months
Pro
ba
bilit
y (
%)
No Portal pressure, Bili <1
Portal pressure, Bili <1
Portal pressure, Bili 1
Llovet JM, et al. Hepatology 1999;30:1434–1440.
Patients selected by Mazzafero
Criteria and Child’s A cirrhosis
Life with Minimal Residual Liver
Reserve
• Stable 49 yrs with PBC who is on the transplant list with MELD of 14
• Underwent emergency repair of incarcerated umbilical hernia (no need for bowel resection)
• 1 week post-op
– Severe ascites
– HRS
– MELD 29
• 2 weeks post-op undergoes successful OLT